Cryosite Ltd
ASX:CTE
Intrinsic Value
Cryosite Ltd. engages in the provision of long term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. [ Read More ]
The intrinsic value of one CTE stock under the Base Case scenario is 0.63 AUD. Compared to the current market price of 0.91 AUD, Cryosite Ltd is Overvalued by 30%.
Valuation Backtest
Cryosite Ltd
Run backtest to discover the historical profit from buying and selling CTE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cryosite Ltd
Current Assets | 9.4m |
Cash & Short-Term Investments | 5.9m |
Receivables | 2m |
Other Current Assets | 1.5m |
Non-Current Assets | 12.8m |
PP&E | 3.9m |
Intangibles | 6k |
Other Non-Current Assets | 8.9m |
Current Liabilities | 4.1m |
Accounts Payable | 1.3m |
Accrued Liabilities | 266k |
Other Current Liabilities | 2.5m |
Non-Current Liabilities | 15.2m |
Long-Term Debt | 2.4m |
Other Non-Current Liabilities | 12.9m |
Earnings Waterfall
Cryosite Ltd
Revenue
|
12.6m
AUD
|
Cost of Revenue
|
-4.9m
AUD
|
Gross Profit
|
7.7m
AUD
|
Operating Expenses
|
-5.9m
AUD
|
Operating Income
|
1.7m
AUD
|
Other Expenses
|
-168.1k
AUD
|
Net Income
|
1.6m
AUD
|
Free Cash Flow Analysis
Cryosite Ltd
CTE Profitability Score
Profitability Due Diligence
Cryosite Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Cryosite Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
CTE Solvency Score
Solvency Due Diligence
Cryosite Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Cryosite Ltd's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTE Price Targets Summary
Cryosite Ltd
Shareholder Return
CTE Price
Cryosite Ltd
Average Annual Return | 196.55% |
Standard Deviation of Annual Returns | 300.22% |
Max Drawdown |
N/A
|
Market Capitalization | 44.4m AUD |
Shares Outstanding | 48 809 563 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cryosite Ltd. engages in the provision of long term storage, supply chain logistics management of pharmaceutical products used in clinical trials and biological materials. The company is headquartered in Sydney, New South Wales. The company went IPO on 2002-05-09. The firm operates through two segments, which include Clinical Trials and Biological Services Logistics, and Cord Blood and Tissue Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological services to the clinical trial and research industry. The Cord Blood and Tissue Storage segment provides long-term storage for cord blood and tissue samples. The firm engages in clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution, and reverse logistics management.
Contact
IPO
Employees
Officers
The intrinsic value of one CTE stock under the Base Case scenario is 0.63 AUD.
Compared to the current market price of 0.91 AUD, Cryosite Ltd is Overvalued by 30%.